<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30613" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Trimethoprim Sulfamethoxazole</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kemnic</surname>
            <given-names>Tyler R.</given-names>
          </name>
          <aff>Michigan State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Coleman</surname>
            <given-names>Meghan</given-names>
          </name>
          <aff>Metro Health Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tyler Kemnic declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Meghan Coleman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30613.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Trimethoprim/sulfamethoxazole, also known as co-trimoxazole, can be abbreviated in the following ways: SXT, TMP-SMX, TMP-SMZ, or TMP-Sulfa. It is an antimicrobial used to treat and prevent many bacterial infections. This drug is very cost-affordable and used for many types of illnesses. The FDA-Approved indications include acute infective exacerbation of chronic bronchitis, otitis media in pediatrics only, travelers diarrhea for treatment and prophylaxis, urinary tract infections, shigellosis, pneumocystis jirovecii, pneumonia/pneumocystis carinii pneumonia (PJP/PCP), and toxoplasmosis, both as prophylaxis and treatment. There are also non-FDA-approved indications. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, toxicity, and monitoring of TMP-SMX so providers can direct patient therapy where necessary for infections as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the antimicrobial mechanism of action of trimethoprim/sulfamethoxazole, focusing on each component individually and the synergism of the combination.</p></list-item><list-item><p>Assess&#x000a0;the approved indications for initiating antimicrobial therapy with trimethoprim/sulfamethoxazole.</p></list-item><list-item><p>Compare&#x000a0;the potential adverse events associated with trimethoprim/sulfamethoxazole.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination and communication to properly use trimethoprim/sulfamethoxazole to improve patient outcomes in infectious disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30613&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30613">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30613.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Trimethoprim/sulfamethoxazole, also known as co-trimoxazole, can be&#x000a0;abbreviated in the following ways: SXT, TMP-SMX, TMP-SMZ, or TMP-sulfa.<xref ref-type="bibr" rid="article-30613.r1">[1]</xref><xref ref-type="bibr" rid="article-30613.r2">[2]</xref> It is an antimicrobial used to treat and prevent many bacterial infections. In 1974, TMP/SMX healthcare professionals began&#x000a0;prescribing the medication, and the drug is now on the list of the World Health Organization's (WHO) essential medicines.<xref ref-type="bibr" rid="article-30613.r3">[3]</xref> This drug is very cost-affordable and used for many types of illnesses.<xref ref-type="bibr" rid="article-30613.r4">[4]</xref></p>
        <p>
<bold>The FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute infective exacerbation of chronic bronchitis</p>
          </list-item>
          <list-item>
            <p>Otitis media in pediatrics only</p>
          </list-item>
          <list-item>
            <p>Travelers diarrhea for treatment and prophylaxis</p>
          </list-item>
          <list-item>
            <p>Urinary tract infections</p>
          </list-item>
          <list-item>
            <p>Shigellosis</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Pneumocystis jirovecii</italic> pneumonia/<italic toggle="yes">Pneumocystis carinii</italic> pneumonia (PJP/PCP), both prophylactic and treatment</p>
          </list-item>
          <list-item>
            <p>Toxoplasmosis, both prophylactic and treatment</p>
          </list-item>
        </list>
        <p>
<bold>The Non-FDA Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Prophylaxis in HIV-infected individuals</p>
          </list-item>
          <list-item>
            <p>Acne vulgaris</p>
          </list-item>
          <list-item>
            <p>Listeria</p>
          </list-item>
          <list-item>
            <p>Melioidosis</p>
          </list-item>
          <list-item>
            <p>Pertussis (whooping cough)</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Staphylococcus aureus</italic> infections, including methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA)</p>
          </list-item>
          <list-item>
            <p>Tuberculosis</p>
          </list-item>
          <list-item>
            <p>Whipple disease</p>
          </list-item>
          <list-item>
            <p>Isosporiasis</p>
          </list-item>
          <list-item>
            <p>Malaria</p>
          </list-item>
          <list-item>
            <p>Community-acquired pneumonia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30613.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Sulfamethoxazole is a sulfonamide (antimicrobial drug class) that works directly on folate synthesis inside microbial organisms, eg, bacteria. Sulfamethoxazole achieves this directly as a competitor of p-aminobenzoic acid (PABA) during the synthesis of dihydrofolate via inhibition of the dihydropteroate synthase. Trimethoprim is a direct competitor of the enzyme dihydrofolate reductase,&#x000a0;resulting in its inhibition, which halts the production of tetrahydrofolate to its active form of folate. Combining these&#x000a0;2 agents is meant to create a synergistic anti-folate effect; tetrahydrofolate is necessary for synthesizing purines required for DNA and protein production. When used alone, these drugs only act in a bacteriostatic manner. However, when combined with sulfamethoxazole-trimethoprim, they block&#x000a0;2 steps in the bacterial biosynthesis of essential nucleic acids and proteins, thus can be bactericidal, eg, urine.<xref ref-type="bibr" rid="article-30613.r5">[5]</xref></p>
        <p>Sulfamethoxazole is a CYP2C9 inhibitor hepatically metabolized by the CYP450 system. Its half-life is 6 to 12 hours, increasing to between 20 and 50 hours in renal failure.&#x000a0;Trimethoprim has a half-life of 8 to 10 hours, is minimally metabolized in the liver, and is primarily excreted in the&#x000a0;urine, essentially unchanged.</p>
      </sec>
      <sec id="article-30613.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Sulfamethoxazole/trimethoprim may be administered orally without regard to meals. However, taking it with at least 8 ounces of water is best. It also has an intravenous formulation. The choice of oral or intravenously varies depending on the type of infection/or type of prophylactic use. It should not be administered intramuscularly. Patients with impaired renal function must have calculated dosing regimens based on renal function, as listed below. Administration of the&#x000a0;2 drugs&#x000a0;is in a&#x000a0;1 to&#x000a0;5 ratio (trimethoprim:sulfamethoxazole) as a tablet formulation; this is so when they enter the body, their concentration throughout the blood/tissues is&#x000a0;1 to 20, which is the peak synergistic desired effect ratio of the&#x000a0;2 drugs in combination.<xref ref-type="bibr" rid="article-30613.r6">[6]</xref></p>
        <p>
<bold>Bacterial Infections</bold>
</p>
        <p>Oral dosage in adults and children weighing 40 kg (88 pounds) or more should have a single tablet of 800 mg of sulfamethoxazole and 160 mg of trimethoprim every 12 hours for 10 to 14 days. Children 2 months and older must have a weight-adjusted dosage.</p>
        <p>
<bold>Treatment of <italic toggle="yes">Pneumocystis jirovecii</italic>&#x000a0;Pneumonia/P<italic toggle="yes">neumocystis </italic>carinii&#x000a0;Pneumonia</bold>
</p>
        <p>Adults/children,&#x000a0;2 months and older: The dose is also weight-adjusted. Usually, 75 to 100 mg per kilogram of body weight&#x000a0;for sulfamethoxazole and 15 to 20 mg per kilogram for trimethoprim daily for 14 to 21 days.<xref ref-type="bibr" rid="article-30613.r6">[6]</xref></p>
        <p>
<bold>Prevention of <italic toggle="yes">Pneumocystis jirovecii</italic> pneumonia/ pneumocystis carinii pneumonia</bold>
</p>
        <p>In adults, 800 mg of sulfamethoxazole and 160 mg of trimethoprim are given daily. In children&#x000a0;2 months of age and older, dosages are determined by body size.<xref ref-type="bibr" rid="article-30613.r6">[6]</xref></p>
        <p>
<bold>Traveler's Diarrhea</bold>
</p>
        <p>In adults, 800 mg of sulfamethoxazole and 160 mg of trimethoprim every 12 hours for&#x000a0;5 days. For children&#x000a0;2 months and older, use and dosage vary.</p>
        <p>
<bold>Chronic Bronchitis</bold>
</p>
        <p>For acute exacerbations due to strains of <italic toggle="yes">Streptococcus pneumoniae</italic> or <italic toggle="yes">Haemophilus influenzae, </italic>1&#x000a0;tablet of 800 mg of sulfamethoxazole and 160 mg of trimethoprim every 12 hours for 10 to 14 days.<xref ref-type="bibr" rid="article-30613.r7">[7]</xref></p>
        <p>
<bold>Shigellosis</bold>
</p>
        <p>Enteritis caused by <italic toggle="yes">Shigella flexneri</italic>&#x000a0;and <italic toggle="yes">Shigella sonnei:</italic> 1 tablet&#x000a0;800 mg of&#x000a0;sulfamethoxazole&#x000a0;and 160 mg of trimethoprim every 12 hours for&#x000a0;5 days; antimicrobial resistance is an increasing concern in this infection.<xref ref-type="bibr" rid="article-30613.r8">[8]</xref></p>
        <p>
<bold>Urinary Tract Infections</bold>
</p>
        <p>
<bold>
<italic toggle="yes">Pyelonephritis</italic>
</bold>
</p>
        <p>One tablet of 800 mg of&#x000a0;sulfamethoxazole&#x000a0;and 160 mg of trimethoprim every 12 hours for 14&#x000a0;days</p>
        <p>
<bold>
<italic toggle="yes">
<bold>Prostatitis</bold>
</italic>
</bold>
</p>
        <p>One tablet of 800 mg of&#x000a0;sulfamethoxazole&#x000a0;and 160 mg of trimethoprim every 12 hours for 14&#x000a0;days or 2 to 3 months if a chronic infection.<xref ref-type="bibr" rid="article-30613.r9">[9]</xref></p>
        <p>
<bold>Acne Vulgaris (Non-FDA Approved)</bold>
</p>
        <p>One&#x000a0;tablet of 800 mg of&#x000a0;sulfamethoxazole&#x000a0;and 160 mg of trimethoprim every 12 hours for 18 days</p>
        <p>
<bold>Community-Acquired Pneumonia (Non-FDA Approved)</bold>
</p>
        <p>One&#x000a0;tablet of 800 mg of&#x000a0;sulfamethoxazole&#x000a0;and 160 mg of trimethoprim every 12 hours for 10 to 14 days</p>
        <p>Renal impairment guidelines are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>CrCl greater than 30 mL per minute with no dose change</p>
          </list-item>
          <list-item>
            <p>CrCl 15 to 30 mL per minute decrease dose by 50%</p>
          </list-item>
          <list-item>
            <p>CrCl less than 15 do not use</p>
          </list-item>
        </list>
        <p>Use is not&#x000a0;recommended&#x000a0;in children younger than&#x000a0;2 months of age.</p>
      </sec>
      <sec id="article-30613.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The primary adverse effects of trimethoprim/sulfamethoxazole include rash, photosensitivity, as well as folate deficiency.<xref ref-type="bibr" rid="article-30613.r10">[10]</xref><xref ref-type="bibr" rid="article-30613.r11">[11]</xref>&#x000a0;A list of the more common side effects includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Loss of appetite</p>
          </list-item>
          <list-item>
            <p>Nausea/vomiting/dyspepsia</p>
          </list-item>
          <list-item>
            <p>Painful or swollen tongue</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Tinnitus</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Insomnia</p>
          </list-item>
          <list-item>
            <p>Rash/urticaria</p>
          </list-item>
          <list-item>
            <p>Anorexia</p>
          </list-item>
          <list-item>
            <p>Photosensitivity</p>
          </list-item>
        </list>
        <p>More serious reactions include Stevens-Johnson syndrome, various anemias, agranulocytosis, <italic toggle="yes">C. diff</italic>.-associated diarrhea, myelosuppression, renal failure/interstitial nephritis, pancreatitis, and hepatotoxicity. Hemolytic anemia can occur with sulfa drugs like sulfamethoxazole in patients with a glucose-6-phosphate-dehydrogenase (G6PD) deficiency. A patient with an unknown sulfa allergy&#x000a0;and treated with trimethoprim/sulfamethoxazole may experience anaphylaxis or less serious yet severe symptoms such as hives, itchy eyes, swelling of the mouth or throat, and abdominal cramping.<xref ref-type="bibr" rid="article-30613.r12">[12]</xref></p>
      </sec>
      <sec id="article-30613.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Trimethoprim/Sulfamethoxazole Contraindications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Known hypersensitivity to either drug or a past sulfa allergy</p>
          </list-item>
          <list-item>
            <p>Pregnancy (FDA pregnancy category D) - due to the inhibition of folate synthesis, which can lead to congenital abnormalities.</p>
          </list-item>
          <list-item>
            <p>Liver parenchymal damage, jaundice, and hepatic failure</p>
          </list-item>
          <list-item>
            <p>Hematological disorders</p>
          </list-item>
          <list-item>
            <p>Renal insufficiency&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Neonate less than&#x000a0;6 weeks of age</p>
          </list-item>
        </list>
        <p>Trimethoprim/sulfamethoxazole is an American pregnancy category D medication. Use during early pregnancy has been related to congenital malformations and maternal folic acid deficiency; this may cause neural tube defects (spina bifida), urinary tract defects, oral clefts, and clubbed feet. Use during late pregnancy has been related to preterm labor. The drug also gets excreted in breast milk, and breastfeeding patients should not use trimethoprim/sulfamethoxazole during this time.&#x000a0;Administration of trimethoprim/sulfamethoxazole should not occur concomitantly with any of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>ACE inhibitors: Risk of hyperkalemia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Prilocaine: Risk of methemoglobinemia</p>
          </list-item>
          <list-item>
            <p>Antiarrhythmics: Risk of QTc prolongation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dapsone: Increases plasma levels of both drugs</p>
          </list-item>
          <list-item>
            <p>Methenamine:&#x000a0;Risk of crystalluria</p>
          </list-item>
          <list-item>
            <p>Rifampin: Risk of reducing trimethoprim plasma concentrations</p>
          </list-item>
          <list-item>
            <p>Sulfonylureas&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Phenytoin: Increase in the half-life of phenytoin</p>
          </list-item>
          <list-item>
            <p>Antifolates: Risk of megaloblastic anemia</p>
          </list-item>
          <list-item>
            <p>Lamivudine, zalcitabine, and zidovudine</p>
          </list-item>
          <list-item>
            <p>Procainamide and/or amantadine&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Clozapine</p>
          </list-item>
          <list-item>
            <p>Digoxin: Increase in digoxin levels</p>
          </list-item>
          <list-item>
            <p>Diuretics: Risk of thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Ciclosporin: Risk of kidney function decline</p>
          </list-item>
          <list-item>
            <p>Spironolactone: Risk of hyperkalemia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30613.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>When initiating therapy with trimethoprim/sulfamethoxazole, some patients may require a baseline blood urea nitrogen and serum creatinine ratio, frequent complete blood counts (CBC), and electrolyte measurements if they have renal impairment or are taking a drug that interacts with potassium.</p>
      </sec>
      <sec id="article-30613.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Overdosing on trimethoprim/sulfamethoxazole is possible, and potential signs of toxicity include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea/vomiting</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Mental depression</p>
          </list-item>
          <list-item>
            <p>Confusion</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Uremia</p>
          </list-item>
          <list-item>
            <p>Loss of appetite</p>
          </list-item>
          <list-item>
            <p>Colic</p>
          </list-item>
          <list-item>
            <p>Drowsiness</p>
          </list-item>
          <list-item>
            <p>Bone marrow depression</p>
          </list-item>
        </list>
        <p>Suppose there is suspicion of a patient having trimethoprim/sulfamethazine toxicity. In that case, a treatment plan includes the administration of activated charcoal (if ingested), gastric lavage, and supportive intravenous (IV) and oral fluids. More severe treatment measures may include hemodialysis and alkalizing the patient's urine.<xref ref-type="bibr" rid="article-30613.r5">[5]</xref></p>
      </sec>
      <sec id="article-30613.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Prescribing clinicians, including nurse practitioners, primary care providers, physician assistants, and internists who prescribe trimethoprim/sulfamethoxazole (TMP-SMX), should know its indications and adverse effects. Also, when a patient receives a prescription of trimethoprim/sulfamethoxazole, some patients may need a baseline blood urea nitrogen and serum creatinine ratio, frequent complete blood counts (CBC), and electrolyte measurements if renal impairment is a known issue or if taking a drug that has interactions with potassium.</p>
        <p>Pharmacists should be consulted to verify coverage with an infectious disease specialist, verify dosing, perform medication reconciliation, and report any concerns to the rest of the healthcare team.&#x000a0;Clinicians&#x000a0;administer the drug to the inpatient. They can also confirm no adverse events resulting from therapy with TMP-SMX, reporting any concerns immediately to the prescriber. In cases of pediatric use or renal impairment, the pharmacist, nurse, and prescriber should coordinate to ensure proper dosing. As with any medication therapy, antimicrobial treatment with TMP-SMX requires an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists collaborating across disciplines to achieve optimal patient outcomes.</p>
      </sec>
      <sec id="article-30613.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30613&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30613">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30613/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30613">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30613.s11">
        <title>References</title>
        <ref id="article-30613.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-Solache</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>The Enterococcus: a Model of Adaptability to Its Environment.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2019</year>
            <month>Mar</month>
            <day>20</day>
            <volume>32</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30700430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30613.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Clinical features, identification, antimicrobial resistance patterns of Nocardia species in China: 2009-2017.</article-title>
            <source>Diagn Microbiol Infect Dis</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>94</volume>
            <issue>2</issue>
            <fpage>165</fpage>
            <page-range>165-172</page-range>
            <pub-id pub-id-type="pmid">30679058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30613.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krooks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weatherall</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Complete Resolution of <italic>Mycobacterium marinum</italic> Infection with Clarithromycin and Ethambutol: A Case Report and a Review of the Literature.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>48</fpage>
            <page-range>48-51</page-range>
            <pub-id pub-id-type="pmid">30666280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30613.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>She</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Chok</surname>
                <given-names>KSH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>IWS</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Sin</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>JYY</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Pneumocystis jirovecii-related spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema in a liver transplant recipient: a case report.</article-title>
            <source>BMC Infect Dis</source>
            <year>2019</year>
            <month>Jan</month>
            <day>18</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <pub-id pub-id-type="pmid">30658592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30613.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eyler</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Shvets</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacology of Antibiotics.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2019</year>
            <month>Jul</month>
            <day>05</day>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>1080</fpage>
            <page-range>1080-1090</page-range>
            <pub-id pub-id-type="pmid">30862698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30613.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weyant</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Kabbani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Doucette</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cervera</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pneumocystis jirovecii: a review with a focus on prevention and treatment.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>12</issue>
            <fpage>1579</fpage>
            <page-range>1579-1592</page-range>
            <pub-id pub-id-type="pmid">33870843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30613.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falcon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iberico</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guerra</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reyes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Felix</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Flores</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Los R&#x000ed;os</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Casas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanchez-Gambetta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carrasco</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A pilot study of safety of sulfamethoxazole, trimethoprim and guaifenesin in pediatric and adult patients with acute bronchitis.</article-title>
            <source>BMC Res Notes</source>
            <year>2019</year>
            <month>Mar</month>
            <day>04</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>119</fpage>
            <pub-id pub-id-type="pmid">30832720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30613.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hosseini Nave</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mansouri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sadeghi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moradi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Molecular diagnosis and anti-microbial resistance patterns among Shigella spp. isolated from patients with diarrhea.</article-title>
            <source>Gastroenterol Hepatol Bed Bench</source>
            <year>2016</year>
            <season>Summer</season>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>205</fpage>
            <page-range>205-10</page-range>
            <pub-id pub-id-type="pmid">27458513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30613.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wan</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>YQ</given-names>
              </name>
            </person-group>
            <article-title>[Pathogens of prostatitis and their drug resistance: an epidemiological survey].</article-title>
            <source>Zhonghua Nan Ke Xue</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>912</fpage>
            <page-range>912-7</page-range>
            <pub-id pub-id-type="pmid">24218946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30613.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brienesse</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levendel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title><italic>Tropheryma whipplei</italic> Endocarditis: Case Presentation and Review of the Literature.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>ofy330</fpage>
            <pub-id pub-id-type="pmid">30648125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30613.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanlon</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Perera</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Drinka</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Crnich</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Schweon</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Klein-Fedyshin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wessel</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Saracco</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mulligan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nace</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>The IOU Consensus Recommendations for Empirical Therapy of Cystitis in Nursing Home Residents.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>539</fpage>
            <page-range>539-545</page-range>
            <pub-id pub-id-type="pmid">30584657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30613.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallardo-Cartagena</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chiappe-Gonzalez</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Astocondor-Salazar</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Salazar-Mesones</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Narcizo Susanibar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cucho-Espinoza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huaroto-Valdivia</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Ticona-Ch&#x000e1;vez</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>[Vibrio cholerae NO-O1/NO-O139 bacteremia in a cirrhotic patient. First case report in Peru and literatura review].</article-title>
            <source>Rev Gastroenterol Peru</source>
            <year>2018</year>
            <season>Jul-Sep</season>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>301</fpage>
            <page-range>301-305</page-range>
            <pub-id pub-id-type="pmid">30540737</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
